NCT07337967 is a clinical trial in B Chronic Lymphocytic Leukemia, sponsored by Huda Ahmed Abdelsabour Abdelwahab.

Who is sponsoring NCT07337967?

NCT07337967 is sponsored by Huda Ahmed Abdelsabour Abdelwahab.

What condition does NCT07337967 study?

NCT07337967 studies B Chronic Lymphocytic Leukemia.

Is NCT07337967 still recruiting?

NCT07337967 is currently not yet recruiting. Last updated 13 January 2026.

Last reviewed 2026-01-13 · How we verify

NCT07337967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms

Not yet recruiting Last updated 13 January 2026

What this trial tests

trial in B Chronic Lymphocytic Leukemia in 120 participants. Not yet recruiting.

Timeline

1 January 2026

Primary endpoint
1 February 2027

1 September 2027

Quick facts

Lead sponsor	Huda Ahmed Abdelsabour Abdelwahab
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 January 2026
Primary completion	1 February 2027
Estimated completion	1 September 2027

Conditions studied

B Chronic Lymphocytic Leukemia — all drugs for B Chronic Lymphocytic Leukemia →

Sponsor

Huda Ahmed Abdelsabour Abdelwahab

Who can join

18 and older, any sex, with B Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07337967 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huda Ahmed Abdelsabour Abdelwahab
Last refreshed: 13 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07337967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing